Mandate

Vinge advises Calliditas

June 10, 2020

Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasdaq Global Select Market in United States.

The trading on The Nasdaq Global Select Market in United States began on 5 June 2020. The total value of the global offering amounts to approximately USD 103.5 million, assuming that the over allotment option is fully exercised.

Calliditas is a specialty pharmaceutical company, focused on the development and commercialization of the product candidate Nefecon, intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin, Hampus Olsson and Julia Hirschberg.

The Scope of Work According to AB 04

One of the most important parts of a construction agreement is the part where the scope of work is defined. There is a major difference between finding scope of work issues early in a construction project, instead of later during the execution phase.
May 04, 2021

A shift in EU merger control policy and practice could affect deal certainty and create opportunities for complainants

The European Commission is expanding its control of mergers and acquisitions within the existing legal framework, allowing national authorities to refer a transaction they do not have jurisdiction over for review in Brussels.
April 26, 2021

Vinge awarded Sweden Law Firm of the Year 2021 by Chambers & Partners

The award, Chambers Europe Award for Excellence – Sweden Law Firm of the Year 2021, is one of the foremost awards a Swedish law firm can receive. Vinge has previously received the award on four occasions.
April 23, 2021